Riskpilot← Back to searchSign inGet full accessLIDDS Pharma AB
ABIn liquidationOrg 5591489421Economic activity was not specified by tax authority · NACE 0000Est. 20180 employees
Revenue 2025
SEK 0
EBITDA margin
—
+168% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK 15K
+168% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK 15K | +168% |
| Net profit | SEK 15K | +168% |
| Total assets | SEK 93K | -3% |
| Equity | SEK 93K | +20% |
| Employees | 0 | — |
Legal name
LIDDS Pharma AB
Org number
5591489421
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
12 februari 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn likvidatorsuppleanten externa firmatecknarna
Company purpose
Bolaget skall bedriva utveckling och kommersialisering av lokalt implanterade medicinleveranssystem och idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | −10 | −1 | −17 | −21 | −23 | −19 | −22 | 15 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — | — | −0 | — |
| EBIT | −10 | −1 | −17 | −21 | −23 | −19 | −22 | 15 |
| Net financials | — | — | — | — | — | — | — | −0 |
| Profit before tax | −10 | −1 | −17 | −21 | −23 | −19 | −22 | 15 |
| Tax | −0 | −0 | −0 | −0 | — | — | −0 | — |
| Net profit | −10 | −1 | −17 | −21 | −23 | −19 | −22 | 15 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 40 | 40 | 66 | 66 | 69 | 68 | 96 | 93 |
| Equity | 40 | 39 | 51 | 51 | 51 | 50 | 78 | 93 |
| Long-term debt | 0 | 0 | 0 | 0 | — | — | 0 | — |
| Short-term debt | 0 | 1 | 15 | 15 | 18 | 18 | 18 | 0 |
| Total debt | — | 1 | 15 | 15 | 18 | 18 | 18 | — |
EBITDA margin
1491000.0%
This company
15.8%
Market median
+9436609% vs market
20182025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182025
Return on equity
15.9%
This company
18.4%
Market median
+14% vs market
20182025
Net profit margin
1485000.0%
This company
8.1%
Market median
+18333233% vs market
20182025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-02-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JA Liquidator | Liquidator | 2026 | — | — |
AM External Signatory | External Signatory | 2026 | — | — |
GU Liquidator | Liquidator | 2026 | — | — |
WL Liquidator | Liquidator | 2026 | — | — |
AS External Signatory | External Signatory | 2026 | — | — |
AM External Signatory | External Signatory | 2026 | — | — |
EÅ Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2026 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2024 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
LIDDS AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LIDDS AB
LIDDS Pharma AB Board members of LIDDS Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Anders Fredrik Lovén | Liquidator | 0 companies |
| Anna Matilda Sjödin | External Signatory | 0 companies |
| Gerd Ulla Marina Jonsson | Liquidator | 0 companies |
| Wendy Lissette Fahlgren | Liquidator | 0 companies |
| Anna Stina Hammarström | External Signatory | 0 companies |
| Aline Madeleine Pettersson | External Signatory | 0 companies |
| Erik Åke Martin Kraft | Chief Auditor | 0 companies |
| Mats Björn Wiking | Deputy Board Member | 0 companies |
| Jan Totte Dahlin | Board of Directors | 0 companies |
| Lars John Anders Månsson | Chairman | 0 companies |
| Jenni Fredrika Björnulfson | Chairman | 0 companies |
| Pontus Göran Ottosson | Deputy Board Member | 0 companies |
| Anja Martina Peters Ohlsson | Board of Directors | 0 companies |
| Matthew John Lindon | Chairman | 0 companies |
| Daniel Martin Lifveredson | Board of Directors | 0 companies |
| Jan Birger Fredrik Törnell | Deputy Board Member | 0 companies |
| Nina Teerés Herne | Chairman | 0 companies |
| Monica Kristina Wallter | Chairman | 0 companies |